Endometriosis Treatment Market Growth Opportunities, Key Drivers, Market Scenario and Forecast to 2030

Increasing investment in the endometriosis treatment market by key stakeholders and growing awareness among women are the major factors expected to drive the growth of the market. The global endometriosis treatment market was valued at US$2.8 billion in 2018 and is expected to grow at a CAGR of around 3% over the forecast period (2019-2030).

The increasing prevalence of endometriosis has fueled the demand for endometriosis treatment across the world. The focus on introducing advanced endometriosis treatment therapeutic options is expected to propel the market growth during the forecast period. Major industry players are dramatically accelerating the development of scientific and clinical therapeutic agents and the launch of new products in the global endometriosis treatment market. This massive push from industry players is expected to boost the future growth of the market.

Key Takeaways from the Endometriosis Treatment Market Research

  • On the basis of the drug, oral contraceptives contributed maximum value share in the global endometriosis treatment market in 2018, due to their high preference as first-line treatment for patients without contraindications and their effectiveness in preventing the recurrence of pelvic pain and endometriotic lesions.
  • The high efficacy of the treatment and its low-risk acceptance should lead to a noticeable share of hormone therapy in the type of treatment.
  • The hospital pharmacy and retail pharmacy segments collectively hold more than 60% of the value share of the endometriosis treatment market, owing to the high pool of patients in hospitals and retail pharmacy visits.
  • Europe captured a notable revenue share of 37% in 2018 and is expected to be the most lucrative region in the global endometriosis treatment market over the forecast period.
  • Increase in government expenditure for high growth of medical industry in emerging economies in Asian region is expected to drive the growth of endometriosis treatment market in this region.

Request a sample PDF brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-3870

Multiple New Indications – Imperative Strategy for Market Players

Increase in the introduction of endometriosis drugs with multiple new indications is a major factor responsible for the intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. launched an innovative new product – Orilissa (elagolix), a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the US market.

What else is in the report?

Future Market Insights (IMF) offers a unique perspective and actionable insights into the endometriosis treatment market in its latest study, presenting a historical demand assessment from 2014-2018 and projections for the period 2019-2030, based on drugs (oral contraceptives, progestins, NSAIDs, GnRH analogues, IUD-LNR and others), type of treatment (hormone therapy and pain management) and distribution channel (hospital pharmacies, retail pharmacies, drugstores and e-commerce ), in seven key regions of the world.

Market segmentation

The global endometriosis treatment market is segmented in detail to cover all aspects of the market and present the reader with a comprehensive approach to market intelligence.

Medication:

  • Oral contraceptives
  • Progestins
  • NSAIDs
  • GnRH analogs
  • NRL-IUD
  • Others

Type of treatment:

  • Hormone therapy
  • pain management

Distribution channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Pharmacies
  • e-commerce

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Request customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-3870

Contents

  1. Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply-side trends

1.4. Analysis and recommendations

  1. Market overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limits

2.3. Inclusions and exclusions

  1. Main market trends

3.1. Key trends impacting the market

3.2. Drug Development Trends

  1. Key factors of success

4.1. Product Adoption / Usage Analysis

4.2. Epidemiology of endometriosis, by key region

4.3. Unmet need for treatment of endometriosis

4.3.1. Potential diagnostic biomarkers for endometriosis

4.3.1.1. Existing and emerging non-invasive diagnostic techniques

4.3.2. Disease Awareness and Educational Strategies for Healthcare Professionals

4.3.3. Drug efficacy and safety, by drug

4.3.4. Marketed and emerging non-hormonal therapies for endometriosis

4.3.5. Disease etiology and pathophysiology

4.4. Research and development strategies

4.4.1. Reformulations and expansion of the labels of currently marketed drugs

4.4.2. GnRH Antagonists Pipeline Assessment

4.4.3. Evaluation of the pipeline of new non-hormonal therapies

4.4.4. Key Strategies Followed by Manufacturers (Alliance, Licensing and Licensing Strategies)

4.4.5. Strategy to maximize return on investment (drug approvals for secondary indication)

4.5. Important Attributes/Factors in Clinical Trials

4.6. History of clinical trials of the main marketed drugs

4.7. Attributes/factors considered for market size of historical evaluation of market size and opportunities of drugs under development

4.8. Pipeline Assessment/Clinical Benchmark Analysis

4.8.1. Marketed/Pipeline Drug Assessment Analysis

4.8.1.1. Therapeutic benefits by drug

4.8.1.2. New drug launches and regulatory approvals, 2019-2030

4.8.1.3. Revenue Opportunity Assessment, 2020-2025

4.8.1.4. Overview of clinical trials and pipeline

4.9. Regulatory scenario

4.10. Refund scenario

4.11. Primary verbatim, opinion of key opinion leaders on future opportunities

Find out before you buy the research report:

https://www.futuremarketinsights.com/ask-question/rep-gb-3870

Explore extensive IMF coverage Health market Perspective Landscape:

The size of the Australian legal cannabis market is expected to reach a market valuation of US$67.39 million by 2022, accelerating with a moderate CAGR of 30.1% by 2022-2032.

The Helicobacter Pylori Testing market share is expected to accumulate US$173.1 million in value by the end of 2022. During the forecast period from 2022 to 2032, a CAGR of 7.4% has been projected for the market, with an expected closing value of US$380.3 million.

Headband Ophthalmoscope Market Value of US$43.5 Million in 2022 and is expected to accumulate a Market Value of US$72.9 Million by registering a CAGR of 4.8% during the forecast period 2022- 2032

About Us

Future Market Insights (ESOMAR certified market research organization and member of the Greater New York Chamber of Commerce) provides in-depth insights into the driving factors that increase demand in the market. It reveals opportunities that will drive market growth in various segments on the basis of source, application, sales channel, and end-use over the next 10 years.

Contact:

Future Market Outlook Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
Such. : +1-845-579-5705
Report:
https://www.futuremarketinsights.com/reports/endometriosis-treatment-market

For sales inquiries: [email protected]
Browse the latest market reports:
https://www.futuremarketinsights.com/reports
LinkedIn|Twitter| Blogs

The Endometriosis Treatment Market growth opportunities, driving factors, market scenario and forecast to 2030 appeared first at Future Market Insights.


Source link

About Chris Y. Camp

Check Also

US sues Idaho over abortion law, cites medical treatment

BOISE, Idaho (AP) — The Justice Department on Tuesday filed a lawsuit challenging Idaho’s restrictive …